Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 EP46 | DOI: 10.1530/endoabs.63.EP46

1Department of Endocrinology, La Rabta Hospital, Tunis, Tunisia; 2Laboratory of Biochemistry, La Rabta Hospital, Tunis, Tunisia; 3Départment of Radiology, La Rabta Hospital, Tunis, Tunisia; 4Department of Radiology, La Rabta Hospital, Tunis, Tunisia.


Introduction: Obesity related disease complications reduce life quality and expectancy and increase health care costs. Non-alcoholic fatty liver disease (NAFLD) is one of the major complications associated with obesity and is considered to be the hepatic manifestation of the metabolic syndrome. Our objective was to determine the prevalence of the NAFLD and to identify its clinical and biological associated factors in women with morbid obesity.

Methods: This was a cross-sectional study involving 50 women with morbid obesity. Patients with a history of chronic alcoholism, known hepatopthy or taking hepatotoxic drugs have been excluded. Metabolic investigations and liver ultrasound were performed in all participants.

Results: The average age of the participants were 34.2±7.51 years with extremes ranging from 18 to 45 years. Metabolic syndrome and NAFLD were diagnosed in 96% and 70% of cases, respectively. HOMA index (4.8±4.7 vs 2.3±1.7, P=0.02), basal insulinemia (19.3±19.8 vs 10.1±7.0, P=0.02), Gamma-glutamyl-transpeptidases (γ GT) level (27.3±12.9 vs 20.5±4.8, P=0.01) and uric acid level (52.81±13.7 vs 45.92±7.4, P=0.03) were significantly higher in patients with NAFLD. However, anthropometric parameters, fasting blood glucose, cholesterol, triglycerides, HDLc, LDLc and transaminases levels were comparable between the two groups. Acanthosis nigricans (P=0.02), hyperinsulinemia (P=0.03), dyslipidemia (P=0.04), and hyperuricemia (P=0.04) were significantly more frequent in patients with NAFLD.

Conclusion: Our results revealed a high prevalence of NAFLD among women with morbid obesity. It was essentially associated with insulin resistance and hyperinsulinemia. Therefore a systematic biological and radiological screening for NAFLD is indicated in morbidly obese patients.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.